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Renal Impairment in Axial Spondyloarthritis: A Prevalent
Condition to Consider
To the Editor:
We read with interest the paper by Couderc, et al1 on the prevalence of renal
impairment in patients with spondyloarthritis (SpA) from the ASAS-
COMOSPA study (Assessment of Spondyloarthritis international Society–
COMOrbidities in SPondyloArthritis). Their results encouraged us to
investigate renal impairment prevalence in our cohort. Renal impairment
[estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2] preva-
lence in the ASAS-COMOSPA cohort was 5.2% and was associated with
age, HLA-B27 positivity, and inflammation in the multivariate analysis.
Data are scarce on the prevalence of renal involvement in SpA with evident
heterogeneity, ranging from 0.1% to 11.3% of the cases2,3,4,5,6,7,8.
      Our cohort comprises 360 patients with axial SpA with data collected
prospectively since their enrollment in an observational study at a tertiary
rheumatology center. We performed a cross-sectional evaluation of data
relating to renal function tests, inflammatory markers, demographics, disease
activity measures, and concomitant cardiovascular disease from the last
followup visit. Continuous data were compared regarding the presence of
renal impairment using the Student t test if the variables presented normal
distribution (previous Shapiro-Wilk test), or Mann-Whitney U test where
appropriate. Chi-square or Fisher’s test was performed if the variable was
categorical. Multivariate analyses were performed with logistic regression
models including variables considered significant in the univariate analysis
and clinically significant variables. 
      Data available from 339 patients were included, and showed a 12.1%
(41 patients) prevalence of renal impairment (eGFR < 60 ml/min/1.73 m2;
Table 1). Age and male sex were significantly associated with renal
impairment. The disease duration was longer in patients with renal
impairment regardless of the age at diagnosis. Cardiovascular comorbidity,
hypertension, and dyslipidemia were more frequently reported in these
patients. Higher Ankylosing Spondylitis Disease Activity Score (ASDAS),
Bath Ankylosing Spondylitis Functional Index (BASFI) score, and
erythrocyte sedimentation rate were significantly associated with renal
impairment, and although there was a similar tendency in the Bath
Ankylosing Spondylitis Disease Activity Index, this did not reach statistical
significance. 
      Regarding treatment, patients with renal impairment were reportedly
taking nonsteroidal antiinflammatory drugs (NSAID) less often. In the
multivariate model, age (OR 1.121, 95% CI 1.054–1.191) and the presence
of dyslipidemia (OR 6.241, 95% CI 1.156–33.692) remained significantly
associated to eGFR < 60 ml/min/1.73 m2. 
      These results show a higher prevalence of renal impairment in our cohort
when compared to the work of Couderc, et al1. This might be explained by
a difference in disease duration between the cohorts, which was much longer
in ours (24.29 ± 15.65 yrs) than in the ASAS-COMOSPA study (mean 8.6
± 9 yrs), as well as our patients being older. Taking into account that disease
duration and age are associated with renal impairment in our cohort, this
may explain the disparity in prevalence. 
     Cardiovascular comorbidities were more frequently reported in the
renal impairment group in both cohorts, although they did not remain statis-
tically associated in the multivariate models. ASDAS and BASFI scores
were higher in both cohorts in the eGFR < 60 ml/min/1.73 m2 group, but
were not associated in the multivariate analysis, highlighting that there is
probably an influence from age and other cofounders. Other significant
differences were the negative association of HLA-B27 positivity with renal
impairment in the ASAS-COMOSPA cohort that we did not confirm in our
cohort. This has only been reported in this paper and further confirmation
is needed in other cohorts. We did also report lesser use of NSAID in the
renal impairment group, which is more the consequence than the cause,
because patients had their treatment adjusted as an outcome of the renal
disease diagnosis. Unfortunately, data on the potential effect of the
cumulative use of NSAID on renal impairment are not available in our
cohort. 
      It is important to highlight that the prevalence of renal impairment can
be significantly high in cohorts with longer SpA disease duration, and this
needs to be taken into consideration when managing these patients. 
Table 1. Comparative analysis of patients with renal impairment (RI) and recorded variables.
Variables                                                                        RI, n = 41                       No RI, n = 298                   p
Age, yrs, mean ± SD                                                    71.12 ± 7.8                       54.64 ± 14.52             < 0.0001*
Male, %                                                                              87.8                                    71.1                       0.024*
Arterial hypertension, %                                                    82.9                                    26.5                     < 0.0001*
Dyslipidemia, %                                                                 46.3                                    29.2                       0.026*
Diabetes mellitus, %                                                          19.5                                     9.7                         0.103
BMI, mean ± SD                                                         28.45 ± 5.72                       26.36 ± 4.39                  0.065
Smokers, %                                                                        69.7                                    56.9                        0.159
HLA-B27+, %                                                                     80                                     84.2                          0.5
axSpA phenotype: AS–nr-axSpA, %                                100–0                               91.6–8.4                     0.056
Disease duration, yrs, mean ± SD                              34.83 ± 13.71                     22.84 ± 15.35             < 0.0001*
Age at diagnosis, yrs, median (IQR)                               33 (22)                               30 ± 16                      0.138
NSAID > 25%, %                                                                22                                     36.4                       0.003*
Biologic use, %                                                                  24.4                                    27.9                        0.641
BASDAI, mean ± SD                                                   4.005 ± 2.1                          3.5 ± 2.13                    0.156
BASFI, mean ± SD                                                        5.2 ± 2.56                           3.5 ± 2.61                < 0.0001*
ASDAS-CRP, mean ± SD                                            2.57 ± 0.87                         2.22 ± 0.92                   0.04*
ASDAS-ESR, mean ± SD                                             2.66 ± 0.9                          2.23 ± 0.87                   0.01*
CRP, median (IQR)                                                        3.8 (6.65)                           3.0 ± 5.65                    0.052
ESR, median (IQR)                                                        15 (23.3)                               8 ± 13                      0.008*
* p < 0.05. BMI: body mass index; axSpA: axial spondyloarthritis; nr-axSpA: nonradiographic axSpA; 
AS: ankylosing spondylitis; IQR: interquartile range; NSAID: nonsteroidal antiinflammatory drugs; BASDAI:
Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index;
ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score using C-reactive protein; ASDAS-ESR: ASDAS
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